

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number  
**WO 01/33976 A1**

- (51) International Patent Classification<sup>7</sup>: **A23L 1/29**, 1/30, 1/305, 1/0522 (74) Agent: MYERS BIGEL SIBLEY SAJOVEC, P.A.; P. O. Box 37428, Raleigh, NC 27627 (US).
- (21) International Application Number: PCT/US00/30731 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date:  
8 November 2000 (08.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/164,043 8 November 1999 (08.11.1999) US
- (71) Applicant (for all designated States except US): **CHILDRENS HOSPITAL LOS ANGELES RESEARCH INSTITUTE** [US/US]; 4650 Sunset Boulevard, Mailstop #84, Los Angeles, CA 90027 (US).
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— With international search report.
- (72) Inventor; and  
(75) Inventor/Applicant (for US only): **KAUFMAN, Francine, R.** [US/US]; 1401 North Bundy Drive, Los Angeles, CA 90049 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR REGULATING BLOOD GLUCOSE AND APPETITE SUPPRESSION IN TYPE 2 DIABETICS



(57) Abstract: Methods are disclosed for treating a patient with Type 2 diabetes to decrease hypoglycemic episodes and/or to diminish fluctuations in blood glucose outside of the normal range, comprising administering to said patient, in a therapeutically-effective amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. Further disclosed is a method of suppressing appetite in a patient with Type 2 diabetes comprising administering to the subject, in an effective appetite suppressing amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. In preferred embodiments, the food composition is in the form of a bar.

WO 01/33976 A1

## **Methods for Regulating Blood Glucose and Appetite Suppression in Type 2 Diabetics**

### **Related Application Information**

- This application claims the benefit of United States Provisional
- 5 Application No. 60/164,043 filed November 8, 1999, which is incorporated by reference herein in its entirety.

### **Field of the Invention**

- The present invention concerns nutritional supplements or food
- 10 compositions that are useful for suppressing appetite, reducing fluctuations in blood glucose levels, and diminishing the incidence of hypoglycemic and hyperglycemic episodes in subjects with Type 2 diabetes mellitus.

### **Background of the Invention**

- 15 Increased longevity in the human population and increased costs of health care have generated considerable interest in alternatives to conventional therapies. Drug therapies are considered a desirable alternative to surgical treatments whenever possible because of the cost savings involved. However, drug therapy can itself become expensive. As a result,
- 20 there is a need for still other approaches, such as nutritional therapies, for various disorders.

- U.S. Patent No. 5,843,921 and 5,606,893 to Kaufman describe a therapeutic food composition that contains a slowly digested complex carbohydrate, particularly uncooked cornstarch, useful for diminishing blood
- 25 sugar fluctuations in diabetic patients, and particularly as a night time snack food.

U.S. Patent No. 5,866,555 to Bell et al. describes a diabetic supplement bar that preferably contains uncooked cornstarch.

U.S. Patent No. 5,902,797 to Bell et al. describes a nutritional supplement bar used to treat appetite suppression and combat weight loss.

Controlling glycemic excursion in subjects with Type 2 diabetes mellitus is an important goal to limit the devastating long-term complications of this disease (The Diabetes Control and Complication Trial Research Group, (1993) *N. Engl. J. Med.* **329**:977; UKPDS Group, (1998) *Lancet* **352**:837). One strategy which has been shown to effectively limit glycemic excursion in patients with Type 1 diabetes has been the use of a snack bar containing uncooked cornstarch (Kaufman et al., (1996) *J. Diabetes Complications* **10**:84; Kaufman et al., (1995) *Diabetes Res. Clin. Pract.* **30**:205; Kaufman et al., (1997) *Diabetes Res. Clin. Pract.* **35**:27) – a complex carbohydrate that is slowly absorbed from the gastrointestinal track over a 6-9 hour period (Chen et al., (1984) *N. Engl. J. Med.* **310**:1721; Lozano et al., (1990) *Am. J. Clin. Nutr.* **52**:667). Kaufman et al. showed a decrease in the incidence of hypoglycemia at midnight and in the morning after the ingestion of a snack bar containing uncooked cornstarch compared to a placebo bar with the same grams of carbohydrate (Kaufman et al., (1996) *J. Diabetes Complications* **10**:84; Kaufman et al., (1995) *Diabetes Res. Clin. Pract.* **30**:205; Kaufman et al., (1997) *Diabetes Res. Clin. Pract.* **35**:27). Of equal importance, there was no increase in observed hyperglycemia after ingesting the cornstarch snack bar.

Accordingly, there is a need in the art for improved methods of treating patients with Type 2 diabetes, in particular, to regulate blood glucose levels. There is a further need in the art for methods of suppressing appetite in subjects with Type 2 diabetes, e.g., to achieve weight loss as part of a therapeutic regime.

30 Summary of the Invention

The present invention is based, in part, on the finding that the food compositions described herein may be used in methods of treating Type 2

diabetic patients to assist in maintaining normoglycemia and to reduce blood glucose fluctuations (*i.e.*, hypoglycemic and/or hyperglycemic episodes). The food compositions may further be employed to suppress appetite (*e.g.*, as part of a weight loss program) for patients with Type 2 diabetes, for whom weight loss or weight control is often a part of the therapeutic regimen.

The investigations described herein were carried out to determine the effects of ingesting a snack bar containing uncooked cornstarch (Extend Bar®, Clinical Products, Limited, Key Biscayne, FL) on nocturnal glycemic excursion in 28 adults (ages 22-78 years) with Type 2 diabetes mellitus (mean HbA1c  $8.21 \pm 1.28\%$ ). Thirteen subjects were treated with oral agents, eight with a combination of insulin and oral agents, and seven with insulin alone. Subjects ingested the study bar (Extend Bar®, containing 30 grams of total carbohydrate, including 5 grams of uncooked cornstarch, 3 grams protein, and 3 grams fat) for 3 evenings followed by a placebo bar for 3 evenings (30 grams of total carbohydrate, 3 grams protein, and 3 grams fat), or vice versa. Pre-snack before bedtime, midnight and before breakfast finger stick blood glucose levels were compared to determine the incidence of hypoglycemia ( $<60$  mg/dL), hyperglycemia ( $>250$ mg/dL), and to calculate any differences in the group's mean blood glucose levels when ingesting the study versus the placebo bar. There were no episodes of hypoglycemia or hyperglycemia. The mean blood glucose levels pre-snack at bedtime were nearly identical (Extend Bar® value  $117.5 \pm 45.6$  mg/dL; placebo bar value  $117.3 \pm 40.0$  mg/dL;  $p=0.977$ ), and lower at midnight and before breakfast on the Extend Bar® nights compared to the placebo bar nights (Extend Bar®, midnight value  $127.9 \pm 31.0$  mg/dL; placebo bar midnight value  $148.2 \pm 32.1$  mg/dL;  $p=0.0001$ ; Extend Bar® breakfast value  $114.2 \pm 15.8$  mg/dL; placebo bar breakfast value  $158.49 \pm 30.3$  mg/dL;  $p<0.0001$ ). These data indicate that ingesting Extend Bar® containing uncooked cornstarch as the nighttime snack reduced the frequency of nocturnal and morning hyperglycemia in subjects with Type 2 diabetes.

Accordingly, one aspect of the present invention are methods of treating a patient with Type 2 diabetes to decrease hypoglycemic episodes

and/or to diminish fluctuations in blood glucose outside of the normal range, comprising administering to said patient, in a therapeutically-effective amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch.

- 5           As a further aspect, the present invention provides a method of suppressing appetite in a patient with Type 2 diabetes in need thereof. The method comprises administering to the subject, in an effective appetite suppressing amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch.
- 10           In preferred embodiments, a food composition or nutritional supplement useful for carrying out the foregoing methods typically comprises:
- (a) about 10 to 75 percent by weight of slowly absorbed complex carbohydrate;
  - (b) about 10 to 40 percent by weight of rapidly absorbed complex
  - 15 carbohydrate;
  - (c) about 2 to 40 percent by weight of protein;
  - (d) about 2 to 40 percent by weight of fat; and
  - (e) at least one sweetening agent in an amount effective to sweeten the food composition.
- 20           In other embodiments, the food composition or nutritional supplement comprises about 20-50 grams of nutrients including about 5-15 grams of uncooked cornstarch.
- Numerous other additives, supplements, and the like can also be included in the composition, as desired.
- 25           The foregoing and other objects and aspects of the present invention are explained in more detail in the drawings herein and the specification set forth below.

#### **Brief Description of the Drawings**

- 30           **Figure 1** is a graphical representation of a comparison between blood glucose levels (mg/dL) in patients pre-snack before bedtime, at midnight, or

before breakfast, with administration of Extend Bar® (left bar) or a placebo (right bar).

### **Detailed Description of Preferred Embodiments**

5           The present invention will now be described with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. This invention may, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be  
10   thorough and complete, and will fully convey the scope of the invention to those skilled in the art.

          Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the  
15   description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the invention and the appended claims, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. All publications, patent applications,  
20   patents, and other references mentioned herein are incorporated by reference in their entirety.

          The present invention provides a food composition for administration to patients with Type 2 diabetes to help maintain proper blood glucose regulation and to prevent wide fluctuations therein, namely, hypoglycemic  
25   and/or hyperglycemic episodes. In addition, the food composition may be administered to regulate blood insulin concentrations, e.g., to reduce the incidence or severity of hyperinsulinemic episodes and/or to prevent fluctuations in blood insulin concentrations. The therapeutic composition may be administered as part of an overall program of treatment for Type 2  
30   diabetes, including control of diet, insulin administration, and/or other medications (e.g., oral hypoglycemic agents) in appropriate cases.

As another aspect, the present invention provides a food composition that may be administered to suppress appetite in a patient with Type 2 diabetes, who is in need or desirous thereof. While not wishing to be limited by any particular theory of the invention, it appears that the appetite  
5 suppressing effects of the inventive food compositions are attributable, at least in part, to three factors: (1) slow absorption of the food composition from the gastrointestinal tract, (2) low glycemic index of the food composition, and (3) stabilization in blood glucose and insulin levels (*i.e.*, reduction in fluctuations in blood glucose and insulin concentrations) following ingestion  
10 of the food composition. Accordingly, the food compositions provided herein may be advantageously employed as part of a weight control regimen for patients with Type 2 diabetes mellitus.

The term "complex carbohydrates" as used herein refers to macromolecular carbohydrates including starches, polydextrose and other  
15 polysaccharides.

The term "sweetening agent" refers to simple sugars (*e.g.*, sucrose, lactose, galactose and fructose), sugar alcohols used as sweeteners (*e.g.*, sorbitol or maltitol) and artificial sweeteners (*e.g.*, aspartame, sodium saccharin and acesulfame potassium).

20 The term "nutrients" as used herein refers to macronutrients such as carbohydrates, proteins and fats.

### **1. Food compositions.**

In general, a food composition used to carry out the present invention  
25 typically comprises:

- a) a complex carbohydrate that is slowly absorbed from the human gastrointestinal tract (hereinafter "slowly absorbed complex carbohydrate"), *i.e.*, is slowly digested and is not completely metabolized even after 3-4 hours;
- b) optionally, but preferably, a complex carbohydrate that is more  
30 rapidly absorbed from the digestive tract (*i.e.*, is essentially completely metabolized after 3-4 hours; hereinafter "rapidly absorbed complex carbohydrate");

- c) optionally, but preferably, protein;
- d) optionally, but preferably, fat; and
- e) optionally, but preferably, at least one sweetening agent.

Food compositions that may be used to carry out the present invention are described in greater detail below. In general, food compositions that may be used to carry out the present invention include those described in U.S. Patent Nos. 5,843,921 and 5,605,893 to Kaufman, subject to the proviso that the food composition may contain simple sugars, and further it is not critical that the amount of simple sugars other than fructose in the composition be less than about 3 grams per unit. Food compositions that may be used to carry out the present invention further include those described in U.S. Patent No. 5,866,555 to Bell et al. and U.S. Patent No. 5,902,797 to Bell et al., taking note that the complex carbohydrate is therein indicated as preferably a slowly absorbed complex carbohydrate, uncooked cornstarch, as described in U.S. Patent No. 5,843,921 to Kaufman.

The ingredients in the food composition may include any conventional food ingredients of adequate purity and wholesomeness that preferably supply the desired amounts of total calories and percentage of calories from carbohydrates, protein and fat, respectively, and wherein the relative weight ranges of slowly absorbed carbohydrates, rapidly absorbed carbohydrates, protein, fat and simple sugars are as indicated herein.

In one particular embodiment, the food composition preferably contains about 20 to about 50 grams of nutrients per serving or unit (e.g., per bar), including: about 15-35 grams of total carbohydrates (about 5-15 grams of slowly absorbed complex carbohydrate, about 7-20 grams of rapidly absorbed complex carbohydrate and about 0-25 grams (preferably, about 0-15 grams) of simple sugar, sugar alcohol, artificial sweetener, or combination thereof); about 3-20 grams of protein; and about 2-7 grams of fat. Preferably, the bar contains less than about 10 grams of simple sugar other than fructose. More preferably, the bar contains less than about 3 grams of simple sugar other than fructose.



In a further embodiment, the food composition preferably provides about 100-230 calories per serving or unit, of which: about 50-75% are from slowly absorbed and rapidly absorbed complex carbohydrates; about 10-25% are from protein; and about 10-25% are from fat.

5           Uncooked cornstarch is the preferred source of slowly absorbed carbohydrate for purposes of the invention since its carbohydrate content and its rate of metabolism are known and are relatively uniform, and it may be readily formulated into a variety of palatable food compositions. Other possible sources of slowly absorbed carbohydrate are known in the art and  
10       include guar gum, pectin, resistant starch, and the like.

          The food composition containing the foregoing components may be in any conventional "snack" form, e.g., bars, puddings, cookies, wafers, milkshakes, gels and the like, contained within a suitable package such as a bottle, can or wrapper. The food composition may be an extruded, nonbaked  
15       food product. Snack-type bars resembling candy or granola bars, or rapidly consumable packaged gels, are most convenient for storage, handling and administration purposes and, when produced with scores, perforations or grooves thereon, can be easily divided for purposes of administering a fraction of a bar where appropriate. Gels may be provided as an essentially  
20       homogeneous composition in a squeezable consumable package like a toothpaste container to be squeezed directly from the package into the mouth for consumption.

          The food composition may have a weight of 10 to 200 grams, depending upon the manner of packaging and intended manner of  
25       administration. As noted above, the composition may be designed with scores or the like to divide the composition for administration, or the composition may be administered in two or more units of the discrete products.

          In the preferred embodiment of a snack-type bar, the ingredients may  
30       include, by way of illustration, uncooked cornstarch as the slowly absorbed carbohydrate; polydextrose, peanuts, peanut derivatives (e.g., peanut butter), other nuts or nut derivatives as sources of rapidly absorbed carbohydrates, fat

and protein; and other protein sources such as soy protein, whey protein, and casein hydrolysate. Artificial sweeteners (e.g., aspartame or saccharin) may be included in the food composition. Fructose and/or sugar alcohols such as sorbitol and maltitol (e.g., 3-15 grams) are typically the principal sweeteners.

5 Simple sugars (e.g., fructose, sucrose, lactose or galactose) may also be included (preferably, less than about 3 grams, of simple sugars other than fructose), provided that the total nutrient and calorie profile of the finished bar comes within the parameters defined herein. Coloring agents, water, salt, preservatives and other standard ingredients or additives normally used in the

10 preparation of a snack or candy-type bar may be utilized.

## **2. Methods of treatment.**

Subjects that may be treated by the methods described herein are typically human subjects. The subjects may be normal subjects (that is,

15 patients not afflicted with diabetes) or may be subjects afflicted with diabetes (e.g., Type 1 or Type 2 diabetes, preferably Type 2). The subjects may be of any age, including neonatal, juvenile, adolescent and adult (including the elderly), with the dosage or amount of the food composition administered adjusted appropriately.

20 The food compositions disclosed herein may be administered to reduce or prevent the incidence of hypoglycemic and/or hyperglycemic episodes in Type 2 diabetic patients. The present invention further provides methods of administering a food composition, as disclosed herein, to reduce fluctuations in blood glucose levels outside of the normal range (*i.e.*, 60-250 mg/dL).

25 The present invention may be used to suppress appetite in a subject in need thereof. Such subjects may include obese patients, in particular, patients with Type 2 diabetes in whom weight loss is a part of the diabetes treatment plan.

The composition is typically administered in an amount ranging from 10

30 to 200 grams per serving, depending upon the age, weight and condition of the subject. One, 2, 3, or even 4 or more servings may be administered per day, again depending upon the condition of the subject and the purpose of the

treatment. For example, where used to suppress appetite, the composition may be administered as a meal replacement or as a before-meal or between-meal snack.

Many diabetics routinely consume a bedtime snack containing about 30 grams of carbohydrate, often in the form of bread, cereal or milk. By the method of treatment of the present invention, patients suffering from diabetes mellitus (preferably Type 2) are administered in place of, or as part of, their normal evening or pre-bedtime snack (in accordance with their recommended bread and protein exchanges) one to two servings or units of the therapeutic food composition, for example one to two bars prepared in accordance with the invention. The number of units administered, including fractions of a unit (such as half bars), will depend on the age, weight and condition of the patient, whether or not the patient takes insulin or other antidiabetic medication and the patient's nocturnal blood sugar profile as determined by finger stick blood glucose levels or other means of blood sugar management. The goal of the treatment is to prevent blood glucose levels from dropping below 60 mg/dl, defined as hypoglycemia, while not rising above 250 mg/dl, defined as hyperglycemia (*i.e.*, to reduce or prevent wide fluctuations in blood glucose levels). Alternatively stated, the food composition is administered to maintain blood glucose levels within the normal range.

Dosage amounts of less than one unit may be utilized in younger pediatric patients or in patients who have demonstrated relatively little tendency towards nocturnal hypoglycemic events.

Patients may also be treated during the day with doses of the novel food composition, which may be slowly metabolized to the monosaccharide glucose over a period of six to eight hours, instead of receiving primarily simple carbohydrates such as are contained in orange juice or other sugar sources that tend to cause a rapid peak in blood glucose level which subsides quickly.

During waking hours the patient's use of, and hence requirement for, glucose is varied and depends upon the level and type of activity, e.g.,

vigorous exercise. The exact amount and frequency of the actual dose, therefore, will vary by patient and from day to day for each patient. A blood glucose test, usually administered as a finger stick to obtain a blood sample, can be used to monitor daily glucose levels as well as the patient's own  
5 subjective experience of symptoms associated with the onset of hypoglycemia. Therefore, in the practice of this invention sufficient complex carbohydrate is administered in the form of the novel food composition to maintain the blood glucose level somewhat above this level, nominally about 60 mg/dl in the average patient.

10 It will be appreciated by persons of skill in the medical arts generally and in the management of diabetic patients specifically that the composition and method of the present invention are valuable adjuncts to conventional diet management and drug or insulin therapy and can provide an easily administered and accepted modality to avoid excessive peaks and valleys in  
15 blood glucose levels, particularly the severe hypoglycemic episodes which are experienced by many diabetics.

The present invention is illustrated in greater detail in the following non-limiting Examples.

20

### Example 1

#### Materials and Methods

Twenty-eight subjects (11 men and 17 women) with Type 2 diabetes followed in Casa Pacifica Medical Clinic in Ventura, CA were chosen for this study after informed consent was obtained. The mean age of the subjects  
25 was  $61.9 \pm 14.5$  years (range 23 - 78 years), the mean diabetes duration was  $49.7 \pm 53.6$  months (range 2 months - 20 years) and the mean HbA1c was  $8.27 \pm 1.3\%$  (range 6.7 - 10.8%). There were 13 subjects treated with oral agents, 8 with insulin, and 7 with combination therapy. They routinely had a pre-bedtime snack.

30 The 28 study subjects with Type 2 diabetes were randomly assigned to ingest Extend Bar® for 3 evenings followed by a placebo bar for 3 evenings, or vice versa. The content of the two 160 Kcal bars are given in **Table 1**. The

subjects were blinded as to the type of bar they ingested and were instructed to follow their regular diabetes routine during the study period, including having a usual dinner on all study nights. Pre-snack before bedtime, midnight and before breakfast finger stick blood glucose levels were obtained with the patient's home glucose meter and results were recorded by the subject on a data sheet. Results from these determinations were compared to determine the incidence of hypoglycemia (number of glucose readings <60 mg/dL), hyperglycemia (number of glucose readings >250 mg/dL), and to calculate any differences in the group's mean blood glucose levels at the 3 evaluation times when ingesting the cornstarch snack bar versus the placebo bar. Statistical analysis was done with student's t-test.

**Table 1. Content of Extend Bar® versus the Placebo Bar**

	<u>Extend Bar®</u>	<u>Placebo Bar</u>
15	Calories	160
	Total Carbohydrate	31 g
	Uncooked cornstarch	5 g
	Protein	3 g
	Total Fat	3 g
20	Monounsaturated Fat	1 g
	Saturated Fat	1.5 g
	Cholesterol	0 mg

Ingredients: Rice flour, chocolate chips (maltitol, unsweetened chocolate, cocoa butter, soy lecithin, natural flavor), fructose, maltitol syrup, cornstarch (Extend Bar® only), soy protein isolate, rice bran, honey, soybean oil, malt, salt, natural flavor

## **Example 2**

### Results

There were no episodes of hypoglycemia or hyperglycemia pre-snack before bedtime, at midnight or before breakfast during the study period. As

shown in **Figure 1**, the mean blood glucose levels pre-snack at bedtime were nearly identical. However, the mean blood glucose levels were significantly lower at midnight and before breakfast on the nights that the Extend Bar® was ingested compared to the placebo bar. There were no significant  
5 differences in blood glucose levels by type of diabetes treatment regimen. The bars were well tolerated with no episodes of gastrointestinal side effects.

These data indicate that adult subjects with Type 2 diabetes had significant reduction in midnight and fasting blood glucose levels on the nights that the Extend Bar®, containing uncooked cornstarch, was ingested  
10 compared to a placebo bar of equal carbohydrate, protein and fat content but without uncooked cornstarch. This occurred regardless of the treatment regimen followed, with subjects on oral agents, insulin and both showing reduction in fasting and midnight blood glucose levels. Ingestion of Extend Bar® as the nighttime snack before bed may be an effective strategy to  
15 reduce the frequency of nocturnal and morning hyperglycemia in subjects with Type 2 diabetes without increasing the risk of hypoglycemic events.

Uncooked cornstarch is a complex carbohydrate composed of approximately 27% of the linear chain dextrose polymer amylose and 73% of the branched chain dextrose polymer amylopectin (Kaufman et al., (1997)  
20 *Diabetes Res. Clin. Pract.* 35:27). Uncooked cornstarch is converted into maltose and other very small glucose polymers in the small intestine by the hydrolytic effect of pancreatic amylase. Intestinal epithelial enzymes allow for further hydrolysis and the slow absorption that occurs into the portal circulation over at least a 6 hour period (Lozano et al., (1990) *Am. J. Clin.*  
25 *Nutr.* 52: 667).

While not wishing to be held to any particular theory of the invention, as a result of this slow hydrolysis and absorption, and perhaps as a result of mixing the carbohydrate with fat and protein (Kaufman et al., (1997) *Diabetes Res. Clin. Pract.* 35:27), glucose entry into the blood stream may be delayed  
30 even further, extending over a 6 hour period. This may help avoid extremes of glycemic excursion and reduces hyperglycemic and hypoglycemic episodes.

Ingestion of the Extend Bar® resulted in a significant decrease in fasting blood glucose levels. Reduction in fasting glycemia is the goal of the intensive management of Type 2 diabetes. As outlined in the algorithms developed by the UKPDS (UKPDS Group (1998) *Lancet* **352**: 837), the goal of therapy for Type 2 diabetes is to achieve a fasting glucose level between 110 - 120 mg/dL. This goal was achieved in this study for the subjects when they ingested Extend Bar®. These results indicate that Extend Bar® is a useful adjunct to the diabetes regimen for subjects with Type 2 diabetes on insulin, oral agents, or both wishing to eat a snack before bedtime.

10

### Example 3

#### Appetite Suppression

There are several lines of evidence indicating that the Extend Bar® carbohydrate snack bar has an effect on appetite suppression:

1. Studies done in subjects with Type 1 diabetes show that there is a prolonged action of the Extend Bar® carbohydrate snack bar. It is effective in the body for up to 8-9 hours to decrease episodes of hypoglycemia (without increasing episodes of hyperglycemia). These results indicate that the Extend Bar® carbohydrate snack bar, through its slow absorption from the gastrointestinal tract, extends the effect of its 160 calories over a prolonged time period. In addition, Extend Bar® carbohydrate snack bar has now been shown to stabilize blood glucose levels in subjects with Type 2 diabetes. Blood glucose levels at midnight and before breakfast are statistically lower in patients with Type 2 diabetes after Extend Bar® carbohydrate snack bar as compared with a snack of equal calories. Again, these results indicate that there is slow absorption of Extend Bar® carbohydrate snack bar in the gastrointestinal tract.

2. Extend Bar® carbohydrate snack bar has an extremely low glycemic index. Foods with a low glycemic index have been shown to be appetite suppressants. These foods do not cause a rapid increase in glucose entry into the body since they are digested and absorbed slowly. They also do not cause the peaks and valleys of blood glucose levels that are known to adversely affect and stimulate appetite.
3. In a study in normal subjects, the Extend Bar® carbohydrate snack bar formula has been shown to cause a slower rise, a decrease in peak value, and a more gradual decrease in blood glucose and insulin levels when compared with other bars. Ten normal subjects ingested 75 grams of carbohydrate in the form of 2.5 snack bars (Extend Bar® carbohydrate snack bar formula versus a placebo bar of equal total carbohydrate, fat, protein, and calorie content). Detailed analysis of the data showed that there was a significant decrease in the insulin peak at 30 and 120 minutes with Extend Bar® carbohydrate snack bar versus the placebo Bar. There was no difference in the area under the curve for insulin levels between these two bars showing that there was an equivalent amount of carbohydrate absorbed, but with a different time frame of absorption. There was also a higher blood glucose peak with the placebo bar versus the Extend Bar® carbohydrate snack bar at 30 minutes indicating a more rapid absorption of the placebo bar carbohydrate content. The reverse was found at 300 minutes, when the blood glucose level was statistically higher at 300 minutes with the Extend Bar® carbohydrate snack bar. This showed that there was a delay in absorption of the nutrients in the Extend Bar® carbohydrate snack bar. Since peaking of insulin followed by its fall in serum concentration has been shown to stimulate appetite, the failure of the insulin level to peak with Extend Bar® carbohydrate snack bar indicates that it will help control appetite.



**Example 4****Appetite Suppression in Healthy Subjects****5    Criteria.**

This prospective study did not enroll participants at random. Several strict criteria were adhered to in order to complete the evaluation. To be considered for the study, volunteer patients had to be between the ages of 18 and 50, although either males or females were acceptable. Furthermore, their  
10    Body Mass Index (BMI) had to be between 27 and 31 at the time of the study period. BMI was calculated by the following formula:

1) multiply weight in pounds by 703

2) multiply height in inches by height in inches

3) divide the answer in step 1 by the answer in step 2 to obtain BMI

15    Exclusionary criteria were important for patient safety and management. No pregnant or lactating women were allowed to participate. Any history of significant endocrinology disorder such as Type 1 or Type 2 diabetes, hypo- or hyperthyroidism, adrenal disorder, or pituitary disease resulted in exclusion. Also, any stated history of eating disorder, such as anorexia nervosa or  
20    bulimia warranted exclusion from the study.

**Methods.**

In an effort to evaluate the efficacy of Extend Bar®, 50 participants were enlisted and randomly assigned numbers to denote patient identification.  
25    Two buffet-style dinner meals on separate dates were also scheduled. For the first meal, patients 001-025 were given the placebo bar and told to eat it 3 hours prior to the buffet and fast after lunchtime. Patients 026-050 were given the active bar and instructed similarly. For the second meal, scheduled for a separate day, the patients were switched, i.e., patients 001-025 were given  
30    the active bar and patients 026-050 were given the placebo bar. Once again, the instructions regarding intake were the same. During the meal, patients were further told to eat whatever pleased them at the buffet and to consume only the amount of food that would be required to achieve satiation.

Overloading of food was strongly discouraged, although unlimited returns to the buffet were allowed. All 50 participants showed for the first meal, but only 41 showed for the second meal thus necessitating the need to schedule the final 9 for the second meal again. After completing each scheduled meal, participants were given a survey as to their satisfaction of the study and to specifically rate the taste and texture of the two bars in a comparison, giving scores for the placebo and active within a range of 1 to 10, with 10 being superior. Additionally, during each meal, each patient was designated by identification number and a caloric intake value was tabulated. Caloric intake was assessed by weighing each portion of food taken prior to ingestion at each separate trip to the buffet table per individual; after consuming the food, the uneaten portions were also weighed in order to accurately assess the amount of caloric intake during the meal.

## 15 **Results.**

For the pool of 50 patients, the distribution between genders was 32 females and 18 males. Average height was 66.96 inches, average weight was 182.6 pounds, and the average BMI was 28.54.

Since patients were identified previously to each meal as receiving either active or placebo, it was then possible to statistically analyze the data in regards to two key components of this trial. First, taste was evaluated. With  $p < 0.05$  using ANOVA (single factor) and t-Test (two-sample assuming unequal variances), the taste of the placebo was rated statistically significantly better than the taste of the active. The patients rated taste for placebo averaging a score of 7.5 out of 10 for level of satisfaction as compared with active which averaged 6.08. Variance between the two series was 1.969 and 5.686 respectively. Using ANOVA, the P-value with one degree of freedom was  $4.69 \times 10^{-5}$  for the differential between taste of placebo versus active, substantiating statistical significance. T-Test further asserted that the P-value was  $2.51 \times 10^{-5}$ , also statistically significant.

Assessing the caloric intake similarly, patients on placebo bar consumed an average of 879.36 calories while active bar consumption

yielded a caloric intake of 697.12 calories for the meal. This corresponds to an average difference of 182.24 calories between the two groups, approximately a 21% decline in caloric intake after consuming the active product. Statistical significance was shown as above in the taste analysis.

- 5 ANOVA provided a P-value of  $1.014 \times 10^{-3}$  with one degree of freedom and t-test analysis supplied a P-value of  $5.12 \times 10^{-4}$ .

The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. Preferred embodiments of the invention are  
10 defined by the following claims, with equivalents of the claims to be included therein.

**I claim:**

1. A method of treating a patient with Type 2 diabetes to decrease hypoglycemic episodes, comprising administering to said patient, in a therapeutically-effective amount, a food composition comprising:
  - (a) about 10 to 75 percent by weight of slowly absorbed complex carbohydrate;
  - (b) about 10 to 40 percent by weight of rapidly absorbed complex carbohydrate;
  - (c) about 2 to 40 percent by weight of protein;
  - (d) about 2 to 40 percent by weight of fat; and
  - (e) at least one sweetening agent in an amount effective to sweeten said food composition.
2. The method of Claim 1, wherein the food composition is administered to the patient as an evening or pre-bedtime snack.
3. The method of Claim 1, wherein the composition comprises per serving or unit about 15-35 g of total carbohydrates.
4. The method of Claim 1, wherein the sweetening agent includes about 10 to 60 percent by weight of a simple carbohydrate selected from the group consisting of sucrose, glucose, dextrose, and combinations thereof.
5. The method of Claim 1, wherein the sweetening agent includes about 2 to 60 percent by weight of a sugar alcohol selected from the group consisting of sorbitol malitol, and combinations thereof.
6. The method of Claim 1, wherein the sweetening agent includes about 2 to 60 percent by weight of fructose.

7. The method of Claim 1, wherein the amount of simple sugars other than fructose in the composition is less than about 40 percent by weight.
8. The method of Claim 1, wherein the sweetening agent is  
5 selected from the group consisting of aspartame, sodium saccharin and acesulfame potassium.
9. The method of Claim 1, wherein the food composition is in the form of a snack bar, pudding, cookie, wafer, milkshake or gel.  
10
10. The method of Claim 1, wherein the food composition has a weight of 10 to 200 grams.
11. The method of Claim 1, wherein the composition is administered  
15 during the daytime to maintain blood glucose levels in a patient engaging in exercise.
12. A method of treating a patient with Type 2 diabetes to diminish fluctuations in blood glucose levels, comprising administering to said patient,  
20 in a therapeutically-effective amount, a food composition comprising:
- (a) about 10 to 75 percent by weight of slowly absorbed complex carbohydrate;
  - (b) about 10 to 40 percent by weight of rapidly absorbed complex carbohydrate;
  - 25 (c) about 2 to 40 percent by weight of protein;
  - (d) about 2 to 40 percent by weight of fat; and
  - (e) at least one sweetening agent in an amount effective to sweeten said food composition.
- 30 13. A method of treating a patient with Type 2 diabetes to decrease hypoglycemic episodes, comprising administering to said patient, in a therapeutically-effective amount, a food composition comprising per serving or

unit about 20-50 grams of nutrients including about 5-15 g of uncooked cornstarch.

14. A method of treating a patient with Type 2 diabetes to diminish  
5 fluctuations in blood glucose levels, comprising administering to said patient, in a therapeutically-effective amount, a food composition comprising per serving or unit about 20-50 grams of nutrients including about 5-15 g of uncooked cornstarch.

10 15. A method of suppressing appetite in a patient with Type 2 diabetes, comprising administering to the subject, in an effective appetite suppressing amount, a food composition comprising:

- (a) about 10 to 75 percent by weight of slowly absorbed complex carbohydrate;
- 15 (b) about 10 to 40 percent by weight of rapidly absorbed complex carbohydrate;
- (c) about 2 to 40 percent by weight of protein;
- (d) about 2 to 40 percent by weight of fat; and
- (e) at least one sweetening agent in an amount effective to sweeten  
20 the food composition.

16. The method of Claim 15, wherein the slowly absorbed complex carbohydrate is uncooked cornstarch.

25 17. The method of Claim 15, wherein the sweetening agent includes about 10 to 60 percent by weight of a simple carbohydrate selected from the group consisting of sucrose, glucose, dextrose, and combinations thereof.

18. The method of Claim 15, wherein the sweetening agent includes  
30 about 2 to 60 percent by weight of a sugar alcohol selected from the group consisting of sorbitol, malitol, and combinations thereof.

19. The method of Claim 15, wherein the sweetening agent includes about 2 to 60 percent by weight of fructose.

20. The method of Claim 15, wherein the amount of simple sugars  
5 other than fructose in the composition is less than about 40 percent by weight.

21. The method of Claim 15, wherein the sweetening agent is selected from the group consisting of aspartame, sodium saccharin and acesulfame potassium.


10

22. The method of Claim 15, wherein the food composition is in the form of a snack bar, pudding, cookie, wafer, milkshake or gel.

23. The method of Claim 15, wherein the food composition has a  
15 weight of 10 to 200 grams.

24. A method of suppressing appetite in a patient with Type 2 diabetes, comprising administering to said subject, in an effective appetite suppressing amount, a food composition comprising per serving or unit about  
20 20-50 grams of nutrients including about 5-15 g of uncooked cornstarch.

FIGURE 1





# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/30731

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A23L1/29 A23L1/30 A23L1/305 A23L1/0522

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 843 921 A (KAUFMAN FRANCINE R) 1 December 1998 (1998-12-01) cited in the application column 2, line 57 - line 61; claims 1,6,30; example 3 ---	1-3, 5-16, 18-24
X	US 5 605 893 A (KAUFMAN FRANCINE R) 25 February 1997 (1997-02-25) cited in the application column 2, line 44 - line 48; claims 1,13; example 1 ---	1-3, 7-16, 20-24
X	US 5 866 555 A (BELL STACEY J ET AL) 2 February 1999 (1999-02-02) cited in the application claims 1,10 ---	13,14,24
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

20 February 2001

Date of mailing of the international search report

26. 02. 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Heezius, A

# INTERNATIONAL SEARCH REPORT

International Application No  
 PCT/US 00/30731

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 902 797 A (BELL STACEY J ET AL) 11 May 1999 (1999-05-11) cited in the application column 2, line 52 -column 3, line 40; claims 1,5 -----	1-24
A	EP 0 749 697 A (HERCULES INC) 27 December 1996 (1996-12-27) page 4, line 13 - line 36 -----	1-24
E	US 6 156 738 A (BELL STACEY J ET AL) 5 December 2000 (2000-12-05) claims 1,12; examples -----	13,14,24

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 00/30731

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5843921	A	01-12-1998	US 5605893 A	25-02-1997
			AU 5085298 A	15-05-1998
			EP 0952838 A	03-11-1999
			WO 9817286 A	30-04-1998
			AU 718692 B	20-04-2000
			AU 3372895 A	23-10-1996
			BR 9507944 A	02-09-1997
			CA 2191714 A	10-10-1996
			CN 1152254 A	18-06-1997
			EP 0765126 A	02-04-1997
			FI 964884 A	06-02-1997
			JP 11500625 T	19-01-1999
			NZ 292038 A	24-09-1998
			WO 9631129 A	10-10-1996
			ZA 9507800 A	06-05-1996
			AU 690654 B	30-04-1998
			AU 1993395 A	03-10-1995
			BR 9507066 A	30-09-1997
			CA 2185425 A	21-09-1995
			EP 0750504 A	02-01-1997
			JP 9512792 T	22-12-1997
			WO 9524906 A	21-09-1995
			ZA 9502124 A	11-12-1995
US 5605893	A	25-02-1997	AU 718692 B	20-04-2000
			AU 3372895 A	23-10-1996
			BR 9507944 A	02-09-1997
			CA 2191714 A	10-10-1996
			CN 1152254 A	18-06-1997
			EP 0765126 A	02-04-1997
			FI 964884 A	06-02-1997
			JP 11500625 T	19-01-1999
			NZ 292038 A	24-09-1998
			WO 9631129 A	10-10-1996
			US 5843921 A	01-12-1998
			ZA 9507800 A	06-05-1996
			AU 690654 B	30-04-1998
			AU 1993395 A	03-10-1995
			BR 9507066 A	30-09-1997
			CA 2185425 A	21-09-1995
			EP 0750504 A	02-01-1997
			JP 9512792 T	22-12-1997
			WO 9524906 A	21-09-1995
			ZA 9502124 A	11-12-1995
US 5866555	A	02-02-1999	AU 2556897 A	07-11-1997
			BR 9708656 A	04-01-2000
			CN 1215311 A	28-04-1999
			EP 0896516 A	17-02-1999
			JP 2000509258 T	25-07-2000
			WO 9738593 A	23-10-1997
			US 6156738 A	05-12-2000
US 5902797	A	11-05-1999	NONE	
EP 0749697	A	27-12-1996	AU 713404 B	02-12-1999
			AU 5614296 A	09-01-1997
			CA 2179696 A	23-12-1996

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/30731

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 00 80731

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

information on patent family members

Int. .onal Application No

PCT/US 00/30731

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0749697 A		FI 962539 A	23-12-1996
		JP 9000172 A	07-01-1997
		NO 962628 A	23-12-1996
US 6156738 A	05-12-2000	US 5866555 A	02-02-1999
		AU 2556897 A	07-11-1997
		BR 9708656 A	04-01-2000
		CN 1215311 A	28-04-1999
		EP 0896516 A	17-02-1999
		JP 2000509258 T	25-07-2000
		WO 9738593 A	23-10-1997

